AbbVie Announces Positive Phase 3 Atogepant (QULIPTA™

NORTH CHICAGO, Ill., March 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the Phase 3 PROGRESS trial evaluating atogepant (QULI...

Related Keywords

United States , American , , Instagram , Linkedin , American Migraine Foundation , Twitter , Drug Administration , International Classification Of Headache Disorders , Exchange Commission , International Burden Of Migraine Study , Youtube , European Union , Allergan , Facebook , United States Focused , European Union Focused , Prescribing Information , Allergan Aesthetics , Private Securities Litigation Reform Act , Quarterly Reports , Classification Committee , International Headache Society , International Classification , Headache Disorders , Vie Announces Positive Phase , Only Oral , Antagonist Specifically Developed , Preventive Treatment , Facts About , American Migraine , Pain Headache , Neurol Neurosurg , Chronic Migraine Epidemiology , International Burden , Migraine Study , Mayo Clin ,